OpGen - Spezialist gegen antibiotikaresistente Infektionen (Seite 24)
eröffnet am 13.08.15 09:48:54 von
neuester Beitrag 10.11.23 14:21:39 von
neuester Beitrag 10.11.23 14:21:39 von
Beiträge: 402
ID: 1.217.076
ID: 1.217.076
Aufrufe heute: 0
Gesamt: 36.934
Gesamt: 36.934
Aktive User: 0
ISIN: US68373L4068 · WKN: A3D38S · Symbol: 650
0,4140
EUR
-1,43 %
-0,0060 EUR
Letzter Kurs 08:04:30 Stuttgart
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 8,1400 | +20,41 | |
| 0,8232 | +17,25 | |
| 1,0900 | +15,96 | |
| 0,6600 | +15,79 | |
| 5,0100 | +15,70 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Leute, wie ist die Lage an der Front?
Hat sich der Kurs nach meinem Ausstieg im März jetzt mitlerweile wieder auf ein Niveau korrigiert, wo man einsteigen kann?
Quartalszahlen kommen am 07. Mai, sagt ihr?
Curetis übernommen, sagt ihr?
Eine neu zusammengestellte Board of Directors, sagt ihr?
Submission to FDA for clearance of the Acuitas® AMR Gene Panel is nearing completion, sagt ihr?
Der Kurs fällt unter 2€, sagt ihr?
Hmmmmhhhhh, es wird so langsam interessant.
Aber ich warte noch.
Wenn 1,60€ in greifbarer Nähe sind, schnappe ich vielleicht zu.
Hat sich der Kurs nach meinem Ausstieg im März jetzt mitlerweile wieder auf ein Niveau korrigiert, wo man einsteigen kann?
Quartalszahlen kommen am 07. Mai, sagt ihr?
Curetis übernommen, sagt ihr?
Eine neu zusammengestellte Board of Directors, sagt ihr?
Submission to FDA for clearance of the Acuitas® AMR Gene Panel is nearing completion, sagt ihr?
Der Kurs fällt unter 2€, sagt ihr?
Hmmmmhhhhh, es wird so langsam interessant.
Aber ich warte noch.
Wenn 1,60€ in greifbarer Nähe sind, schnappe ich vielleicht zu.
Antwort auf Beitrag Nr.: 63.472.364 von Growth2012 am 27.04.20 22:22:01
Super Video
https://m.youtube.com/watch?feature=youtu.be&v=BY-3ySrqDKg
Antwort auf Beitrag Nr.: 63.472.160 von Growth2012 am 27.04.20 22:09:27 after the close of the U.S. financial markets on Thursday, May 7, 2020.
Good sign (Thursdays AH timing), for upcoming good news/numbers 💲💲💲
Good sign (Thursdays AH timing), for upcoming good news/numbers 💲💲💲
OpGen to Provide Business Update and Financial Results for the First Quarter 2020
https://finance.yahoo.com/news/opgen-business-financial-resu…
Wem es interessiert:-Conference Call Details
U.S. Dial-in Number:
+1 (844) 420-8185
International Dial-in Number:
+1 (216) 562-0481
Webcast: https://edge.media-server.com/mmc/p/iggnmjim
Conference ID: 8595009
Reply Details
U.S. Dial-in Number:
+1 (855) 859-2056
International Dial-in Number:
+1 (404) 537-3406
Conference ID:8595009
Following the conclusion of the conference call, a replay will be available through May 14, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.
https://finance.yahoo.com/news/opgen-business-financial-resu…
Wem es interessiert:-Conference Call Details
U.S. Dial-in Number:
+1 (844) 420-8185
International Dial-in Number:
+1 (216) 562-0481
Webcast: https://edge.media-server.com/mmc/p/iggnmjim
Conference ID: 8595009
Reply Details
U.S. Dial-in Number:
+1 (855) 859-2056
International Dial-in Number:
+1 (404) 537-3406
Conference ID:8595009
Following the conclusion of the conference call, a replay will be available through May 14, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.
Antwort auf Beitrag Nr.: 63.218.847 von Growth2012 am 02.04.20 19:06:48
Zitat von Growth2012: Na also....
![]()
...halllooooooo Echo, keiner mehr da?!?📈
P.S. die tickende Zeitbombe sollte (wenn alles gut geht )ab dem 8.05 rum so richtig zünden 💣👏
📈Trading Spotlight
COVID-19 Patients Need to be Tested for Bacteria and Fungi, Not Just the Coronavirus
https://blogs.scientificamerican.com/observations/covid-19-p…
An estimated one in seven COVID-19 patients will develop a secondary infection while hospitalized. Further, a separate study found that only about 50 percent of patient deaths were due to the original viral infection, while the other 50 percent were caused by subsequent secondary infections.
https://blogs.scientificamerican.com/observations/covid-19-p…
An estimated one in seven COVID-19 patients will develop a secondary infection while hospitalized. Further, a separate study found that only about 50 percent of patient deaths were due to the original viral infection, while the other 50 percent were caused by subsequent secondary infections.
Antwort auf Beitrag Nr.: 63.352.753 von stockjumper am 16.04.20 20:31:33Yep, this is deffo"VERY BIG"
OPGN (ab sofort gemerged) auf einem Blick
https://finviz.com/quote.ashx?t=OPGN
P.S. und die Amis finden offensichtlich gefallen daran 2.7000+0.4000 (+17.39%)
OPGN (ab sofort gemerged) auf einem Blick
https://finviz.com/quote.ashx?t=OPGN
P.S. und die Amis finden offensichtlich gefallen daran 2.7000+0.4000 (+17.39%)
NEWS!!!
OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study
04.16.20
Download PDF
Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs
NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated
The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than 2,000 patients collected at nine medical centers across the U.S.
VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) has been pre-published in the Journal of Clinical Microbiology. The study was performed by its newly acquired subsidiaries Ares Genetics GmbH and Curetis GmbH, and scientists at the Max Perutz Labs (Austria), a joint venture of the University of Vienna and the Medical University of Vienna, and the Mayo Clinic (Rochester, MN, U.S.A.).
The article titled, “Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial” (Ref. 1) reports on a study evaluating the performance of pathogen identification and antibiotic susceptibility testing based on whole genome DNA sequencing (WGS) using Ares Genetics’ AI-powered cloud-based bioinformatics platform ares-genetics.cloud and its underlying reference database, ARESdb.
WGS-predicted susceptibility to antibiotics showed 89% categorical agreement with the current reference method of broth microdilution susceptibility testing across a total of 129 pathogen-drug pairs analyzed. Categorical agreement exceeded 90% in 78, and reached 100% in 32 pathogen-drug pairs. For the taxonomic identification of the isolated bacterial pathogens, WGS showed 99% and 93% concordance with the MALDI-ToF reference method at the genus and species levels, respectively.
The study evaluating the AI-powered ares-genetics.cloud platform and the underlying ARESdb reference database included 12 pathogenic bacterial species and 21 antibiotic compounds covering common lower respiratory tract pathogens and is likely one of the most comprehensive peer-reviewed reports on the performance of WGS in predicting susceptibility to antibiotics in a multi-center U.S. trial.
Dr. Andreas Posch, CEO of Ares Genetics and senior author of the study, commented, “This multi-center study clearly demonstrates the feasibility and potential of next-generation sequencing based antibiotic susceptibility testing using our AI-powered cloud platform. Already today, we are offering cloud-based data interpretation and next-generation sequencing services for research use which we intend to roll out more broadly based on these validating results. Equally important, we learned through the study how to optimize our reference database, ARESdb, and improve our predictive models to further advance to applications in clinical practice.”
In this study, the investigators analyzed WGS data of a total of 620 bacterial strains isolated from more than 2,000 clinical samples collected from patients with suspected lower respiratory tract infections at nine hospitals across the U.S. The samples were originally collected for a U.S.-FDA study for the validation of the now FDA-cleared Unyvero LRT syndromic multiplex PCR panel by Curetis. Species identity of the isolated pathogens and their susceptibility to antibiotics were analyzed using MALDI-ToF and broth microdilution, respectively, as best-in-class reference methods according to current practice.
The WGS data analysis was performed using Ares Genetics’ proprietary database, ARESdb, with state-of-the-art open-source tools and public data. At the time of the study, ARESdb comprised of curated genotype-phenotype data for approximately 35,000 bacterial strains. To date, ARESdb has further grown containing matched whole-genome sequencing and antibiotic susceptibility data for more than 50,000 bacterial strains and more than 100 antibiotics.
Microbial infections and antibiotic resistance have become major healthcare challenges with rapidly spreading antimicrobial resistance estimated to have caused 700,000 deaths globally in 2016, a number that is projected to dramatically increase to 10 million deaths annually by 2050 if no countermeasures are taken (Ref. 2). At the same time, few novel antibiotics are in development and prominent pharmaceutical companies have cut back their R&D efforts in the infectious diseases space. In the absence of novel treatment options, we believe novel diagnostic approaches to allow for rapid identification of causative pathogens and their susceptibility to available treatment options are urgently needed to guide appropriate therapy of patients while enabling prudent and informed use of antibiotics.
The study was supported through funding provided by the Austrian Research Promotion Agency and the Vienna Business Agency.
References
Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. Ines Ferreira, Stephan Beisken, Lukas Lueftinger, Thomas Weinmaier, Matthias Klein, Johannes Bacher, Robin Patel, Arndt von Haeseler and Andreas E. Posch. 2020. Journal of Clinical Microbiology, DOI: 10.1128/JCM.00273-20
The Review on Antimicrobial Resistance. 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance, chaired by Jim O’Neill, Wellcome Trust & HM Gove
For further information, please register on the Ares Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbH
Karl-Farkas-Gasse 18
A-1030 Wien
Austria
Email: services@ares-genetics.com
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Panels and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding the development of diagnostic tests by subsidiaries of OpGen. Such statements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen Contact:
Michael Farmer
Vice President, Marketing
(240) 813-1284
mfarmer@opgen.com
Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
Investor Contact:
Joe Green
Edison Group
jgreen@edisongroup.com
OpGen.jpg
https://ir.opgen.com/news-releases/news-release-details/opge…
OpGen Subsidiary Ares Genetics Demonstrates Feasibility and Potential of Next Generation Sequencing Based Antibiotic Susceptibility Testing in Multi-Center Study
04.16.20
Download PDF
Peer-reviewed study evaluated performance of AI-powered bioinformatics cloud platform, ares-genetics.cloud, for NGS-based antibiotic susceptibility testing on 12 pathogenic bacterial species and 21 antibiotic drugs
NGS-based testing reached 100% agreement with reference culture-based testing for 32 pathogen-drug pairs and 89% across all 129 pathogen-drug combinations evaluated
The comprehensive study on NGS-based antibiotic susceptibility testing was based on 620 isolates from more than 2,000 patients collected at nine medical centers across the U.S.
VIENNA, Austria and GAITHERSBURG, Md., April 16, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that a study on the feasibility and potential of antibiotic susceptibility testing and bacterial pathogen identification using next-generation sequencing (NGS) has been pre-published in the Journal of Clinical Microbiology. The study was performed by its newly acquired subsidiaries Ares Genetics GmbH and Curetis GmbH, and scientists at the Max Perutz Labs (Austria), a joint venture of the University of Vienna and the Medical University of Vienna, and the Mayo Clinic (Rochester, MN, U.S.A.).
The article titled, “Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial” (Ref. 1) reports on a study evaluating the performance of pathogen identification and antibiotic susceptibility testing based on whole genome DNA sequencing (WGS) using Ares Genetics’ AI-powered cloud-based bioinformatics platform ares-genetics.cloud and its underlying reference database, ARESdb.
WGS-predicted susceptibility to antibiotics showed 89% categorical agreement with the current reference method of broth microdilution susceptibility testing across a total of 129 pathogen-drug pairs analyzed. Categorical agreement exceeded 90% in 78, and reached 100% in 32 pathogen-drug pairs. For the taxonomic identification of the isolated bacterial pathogens, WGS showed 99% and 93% concordance with the MALDI-ToF reference method at the genus and species levels, respectively.
The study evaluating the AI-powered ares-genetics.cloud platform and the underlying ARESdb reference database included 12 pathogenic bacterial species and 21 antibiotic compounds covering common lower respiratory tract pathogens and is likely one of the most comprehensive peer-reviewed reports on the performance of WGS in predicting susceptibility to antibiotics in a multi-center U.S. trial.
Dr. Andreas Posch, CEO of Ares Genetics and senior author of the study, commented, “This multi-center study clearly demonstrates the feasibility and potential of next-generation sequencing based antibiotic susceptibility testing using our AI-powered cloud platform. Already today, we are offering cloud-based data interpretation and next-generation sequencing services for research use which we intend to roll out more broadly based on these validating results. Equally important, we learned through the study how to optimize our reference database, ARESdb, and improve our predictive models to further advance to applications in clinical practice.”
In this study, the investigators analyzed WGS data of a total of 620 bacterial strains isolated from more than 2,000 clinical samples collected from patients with suspected lower respiratory tract infections at nine hospitals across the U.S. The samples were originally collected for a U.S.-FDA study for the validation of the now FDA-cleared Unyvero LRT syndromic multiplex PCR panel by Curetis. Species identity of the isolated pathogens and their susceptibility to antibiotics were analyzed using MALDI-ToF and broth microdilution, respectively, as best-in-class reference methods according to current practice.
The WGS data analysis was performed using Ares Genetics’ proprietary database, ARESdb, with state-of-the-art open-source tools and public data. At the time of the study, ARESdb comprised of curated genotype-phenotype data for approximately 35,000 bacterial strains. To date, ARESdb has further grown containing matched whole-genome sequencing and antibiotic susceptibility data for more than 50,000 bacterial strains and more than 100 antibiotics.
Microbial infections and antibiotic resistance have become major healthcare challenges with rapidly spreading antimicrobial resistance estimated to have caused 700,000 deaths globally in 2016, a number that is projected to dramatically increase to 10 million deaths annually by 2050 if no countermeasures are taken (Ref. 2). At the same time, few novel antibiotics are in development and prominent pharmaceutical companies have cut back their R&D efforts in the infectious diseases space. In the absence of novel treatment options, we believe novel diagnostic approaches to allow for rapid identification of causative pathogens and their susceptibility to available treatment options are urgently needed to guide appropriate therapy of patients while enabling prudent and informed use of antibiotics.
The study was supported through funding provided by the Austrian Research Promotion Agency and the Vienna Business Agency.
References
Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial. Ines Ferreira, Stephan Beisken, Lukas Lueftinger, Thomas Weinmaier, Matthias Klein, Johannes Bacher, Robin Patel, Arndt von Haeseler and Andreas E. Posch. 2020. Journal of Clinical Microbiology, DOI: 10.1128/JCM.00273-20
The Review on Antimicrobial Resistance. 2016. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance, chaired by Jim O’Neill, Wellcome Trust & HM Gove
For further information, please register on the Ares Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbH
Karl-Farkas-Gasse 18
A-1030 Wien
Austria
Email: services@ares-genetics.com
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Panels and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding the development of diagnostic tests by subsidiaries of OpGen. Such statements constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen Contact:
Michael Farmer
Vice President, Marketing
(240) 813-1284
mfarmer@opgen.com
Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com
Investor Contact:
Joe Green
Edison Group
jgreen@edisongroup.com
OpGen.jpg
https://ir.opgen.com/news-releases/news-release-details/opge…
und zudem, OPGN's Merger mit Curetis ist nun amtlich absolviert 
Merger with Curetis closes
Following approval from both OpGen and Curetis shareholders, the merger between the two companies has now closed. Curetis is a Germany-based molecular diagnostics company with a focus on infectious disease. It has two main business lines: the Unyvero A50 high-plex polymerase chain reaction (PCR) platform for the diagnosis of infectious disease in hospital patients; and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens. Together, OpGen and Curetis had around $6.0m in sales in 2019, up 33% compared to the combined sales of the previous year and at the top end of the original $5–6m guidance for 2019 (given at the time of the merger announcement).
https://www.edisongroup.com/publication/merger-with-curetis-…
...nach soviel "stillzeit", jetzt auf einmal, schlag auf schlag 💲
Merger with Curetis closes
Following approval from both OpGen and Curetis shareholders, the merger between the two companies has now closed. Curetis is a Germany-based molecular diagnostics company with a focus on infectious disease. It has two main business lines: the Unyvero A50 high-plex polymerase chain reaction (PCR) platform for the diagnosis of infectious disease in hospital patients; and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens. Together, OpGen and Curetis had around $6.0m in sales in 2019, up 33% compared to the combined sales of the previous year and at the top end of the original $5–6m guidance for 2019 (given at the time of the merger announcement).
https://www.edisongroup.com/publication/merger-with-curetis-…
...nach soviel "stillzeit", jetzt auf einmal, schlag auf schlag 💲
Durchsuchen
